Ownership and insider activity for Cytokinetics, Incorporated (CYTK): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Price
| Price | $73.45 |
| Market Cap | $9.1B |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $66.9M | $125.2M | $42.3M | $36.4M | $83.0M | $112.7M | $65.6M | $113.0M | $94.9M | $122.5M |
| Short-term Investments | $89.4M | $143.7M | $156.5M | $188.7M | $381.1M | $359.0M | $717.0M | $501.8M | $981.2M | $759.7M |
| Receivables | $24000 | $1.1M | $6.8M | $5.2M | $4.4M | $51.8M | $147000 | $1.3M | $16.6M | $17.8M |
| Inventory | 0 | 0 | -$6.8M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $158.6M | $274.3M | $207.7M | $233.8M | $474.2M | $535.7M | $795.2M | $628.1M | $1.11B | $917.0M |
| Property, Plant & Equipment | $3.6M | $3.6M | $3.2M | $13.4M | $16.3M | $146.4M | $163.2M | $147.7M | $141.0M | $155.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $170.1M | $294.8M | $211.2M | $289.8M | $533.8M | $841.3M | $1.01B | $824.3M | $1.40B | $1.42B |
| Accounts Payable | $4.2M | $5.3M | $3.8M | $8.2M | $8.1M | $21.1M | $25.6M | $21.5M | $20.4M | $22.3M |
| Short-term Debt | $2.5M | 0 | $2.6M | 0 | 0 | 0 | $958000 | $10.1M | $11.5M | $41.2M |
| Total Current Liabilities | $33.3M | $32.4M | $22.2M | $26.0M | $31.2M | $71.9M | $84.6M | $102.7M | $179.7M | $202.5M |
| Long-term Debt | $27.4M | $31.8M | $39.8M | $129.3M | $135.7M | $142.8M | $609.6M | $607.4M | $645.6M | $1.12B |
| Total Liabilities | $75.8M | $185.0M | $185.2M | $300.8M | $420.4M | $597.5M | $1.12B | $1.21B | $1.54B | $2.08B |
| Retained Earnings | -$518.3M | -$646.1M | -$743.3M | -$865.0M | -$992.3M | -$1.21B | -$1.59B | -$2.11B | -$2.70B | -$3.49B |
| Total Equity | $94.4M | $109.8M | $25.9M | -$10.9M | $113.4M | $243.9M | -$107.9M | -$386.3M | -$135.4M | -$659.6M |
| Total Debt | $27.4M | $31.8M | $42.4M | $136.1M | $138.9M | $269.9M | $750.3M | $755.8M | $788.7M | $1.28B |
| Net Debt | -$128.9M | -$237.1M | -$156.3M | -$89.0M | -$325.1M | -$201.7M | -$32.3M | $140.9M | -$287.3M | $402.0M |
| Working Capital | $125.4M | $241.9M | $185.5M | $207.7M | $443.0M | $463.8M | $710.6M | $525.4M | $928.3M | $714.5M |
Financial Health
| Debt / Equity | -7.32 |
| Current Ratio | 6.66 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -1.99 |
Profitability
| Return on Equity | 119.00% |
| Return on Invested Capital | -47.74% |
| Return on Assets | -55.10% |
| Gross Margin | 84.97% |
| Operating Margin | -992.98% |
| Net Margin | -1259.87% |
Related companies: ABVX · AXSM · CORT · CRSP · HALO · JAZZ · MRUS
Explore sector: Healthcare · Biotechnology
More sections of CYTK: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks